Molecular programming of tumor-infiltrating CD8+ T cells and IL15 resistance

Cancer Immunology Research

Volumn 4, Issue 9, 2016, Pages 799-811

  Doedens, Andrew L ^a   Rubinstein, Mark P ^a,b   Gross, Emilie T ^c   Adam Best, J ^a   Craig, David H ^b   Baker, Megan K ^b   Cole, David J ^b   Bui, Jack D ^c   Goldrath, Ananda W ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; CYTOKINE; IMMUNOLOGIC FACTOR; INTERLEUKIN 15 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; LUNG; MEMORY; MOUSE; NONHUMAN; SPLEEN; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, TRANSGENIC; NEOPLASMS; TUMOR BURDEN;

EID: 85016117787     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0178     Document Type: Article

References (60)

1. Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. J Immunol 2014;192:5451-8.
2. Liu K, Catalfamo M, Li Y, Henkart PA, Weng NP. IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U S A 2002;99:6192-7.
3. Tamang DL, Redelman D, Alves BN, Vollger L, Bethley C, Hudig D.Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: Multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine 2006;36:148-59.
4. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68.
5. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409-14.
6. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A 2006;103:9166-71.
7. Stoklasek TA, Schluns KS, Lefrancois L.Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072-80.
8. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-residentCD8+T cells. Cancer Res 2008;68:2972-83.
9. Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, et al. Efficacy and mechanism-of-Action of a novel superagonist interleukin-15: Interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 2013;73:3075-86.
10. Mathios D, Park CK, Marcus WD, Alter S, Rhode PR, Jeng EK, et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer 2016;138: 187-94.
11. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9.
12. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression onHIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-4.
13. Kim PS, Ahmed R.Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010;22:223-30.
14. Schietinger A, Greenberg PD. Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol 2014;35: 51-60.
15. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases frommelanoma patients. J Clin Invest 2011;121:2350-60.
16. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.
17. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
18. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26.
19. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12: 954-61.
20. Davie SA, Maglione JE, Manner CK, Young D, Cardiff RD, MacLeod CL, et al. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res 2007;16:193-201.
21. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol 2013;14:1173-82.
22. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010;70:7465-75.
23. Huang daW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
24. Tripathi S, Pohl MO, Zhou Y, Rodriguez-Frandsen A, Wang G, Stein DA, et al. Meta-And orthogonal integration of influenza "OMICs" data defines a role for UBR4 in virus budding. Cell Host Microbe 2015;18: 723-35.
25. Love MI, Huber W, Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
26. Motz GT, Coukos G.Deciphering and reversing tumor immune suppression. Immunity 2013;39:61-73.
27. Caruso A, Licenziati S, Corulli M, Canaris AD, De FrancescoMA, Fiorentini S, et al. Flow cytometric analysis of activationmarkers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997;27:71-6.
28. Heng TS, Painter MW, Immunological Genome Project C.The Immunological Genome Project: Networks of gene expression in immune cells. Nat Immunol 2008;9:1091-4.
29. Best JA, Blair DA, Knell J, Yang E, Mayya V, Doedens A, et al. Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation. Nat Immunol 2013;14:404-12.
30. Subramanian A, Tamayo P, Mootha VK,Mukherjee S, Ebert BL,Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
31. Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 2012; 37:1130-44.
32. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29-37.
33. Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D.T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 2014;346:98-101.
34. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol 2013;14:1294-301.
35. Wakim LM, Woodward-Davis A, Liu R, Hu Y, Villadangos J, Smyth G, et al. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol 2012;189:3462-71.
36. Cui W, Kaech SM.Generation of effector CD8+T cells and their conversion to memory T cells. Immunol Rev 2010;236:151-66.
37. Sebastian M, Lopez-Ocasio M, Metidji A, Rieder SA, Shevach EM, Thornton AM. Helios controls a limited subset of regulatory T cell functions. J Immunol 2016;196:144-55.
38. Wilkinson B, Chen JY, Han P, Rufner KM, Goularte OD, Kaye J.TOX: An HMG box protein implicated in the regulation of thymocyte selection. Nat Immunol 2002;3:272-80.
39. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R.Antigen-independent memoryCD8T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 2004;101:16004-9.
40. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, HuseniM, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014;26:923-37.
41. Lu HK, Rentero C, Raftery MJ, Borges L, Bryant K, Tedla N.Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases. J Biol Chem 2009;284:34839-48.
42. Rygiel TP, Meyaard L.CD200R signaling in tumor tolerance and inflammation: A tricky balance. Curr Opin Immunol 2012;24:233-8.
43. Lin CC, Bradstreet TR, Schwarzkopf EA, Sim J, Carrero JA, Chou C, et al. Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation. Nat Commun 2014; 5:3551.
44. Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 2016;164:365-77.
45. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013;45:942-6.
46. Tong X, Gui H, Jin F, Heck BW, Lin P, Ma J, et al. Ataxin-1 and Brother of ataxin-1 are components of the Notch signalling pathway. EMBO Rep 2011;12:428-35.
47. Miah MA, Bae YS. Regulation of DC development and DC-mediated T-cell immunity via CISH. Oncoimmunology 2013;2:e23404.
48. Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med 2015;212:2095-113.
49. Han SB, Moratz C, Huang NN, Kelsall B, Cho H, Shi CS, et al. Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. Immunity 2005;22:343-54.
50. Shankar SP, Wilson MS, DiVietro JA, Mentink-Kane MM, Xie Z, Wynn TA, et al. RGS16 attenuates pulmonary Th2/Th17 inflammatory responses. J Immunol 2012;188:6347-56.
51. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S.Integrin-based therapeutics: Biological basis, clinical use and new drugs. Nat Rev Drug Discov 2016; 15:173-83.
52. Wang D, Stewart AK, Zhuang L, Zhu Y, Wang Y, Shi C, et al. Enhanced adaptive immunity inmice lacking the immunoinhibitory adaptor Hacs1. FASEB J 2010;24:947-56.
53. Claudio JO, Zhu YX, Benn SJ, Shukla AH, McGlade CJ, Falcioni N, et al. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Oncogene 2001;20:5373-7.
54. von Holleben M, Gohla A, Janssen KP, Iritani BM, Beer-Hammer S.Immunoinhibitory adapter protein Src homology domain 3 lymphocyte protein 2 (SLy2) regulates actin dynamics and B cell spreading. J Biol Chem 2011;286:13489-501.
55. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011;365:1173-83.
56. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, et al. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2007;2:e1217.
57. Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S, et al. PRR5L degradation promotes mTORC2-mediated PKC-delta phosphorylation and cell migration downstream of Galpha12. Nat Cell Biol 2012;14: 686-96.
58. Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol 2014;9:63-71.
59. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest 2013;123:2604-15.
60. Wherry EJ,Ha SJ, Kaech SM,Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27:670-84.